Evidence map›Paper›PMID 41395729›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Tablet-based Cognitive Assessment Tool (TabCAT) in a multisite study of early-onset Alzheimer's disease.

Wepnyu Yembe Njamnshi, Konstantinos Chiotis, Elena Tsoy, Ganna Blazhenets, Piyush Maiti, Jiaxiuxiu Zhang, Isabel Elaine Allen, Salma Rocha, Ranjani P Shankar, Alinda Amuiri and 45 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Tablet-based Cognitive Assessment Tool (TabCAT) in a multisite study of early-onset Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

55 authors.

Wepnyu Yembe NjamnshiGlobal Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-5082-7960
Konstantinos ChiotisDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-5679-0297
Elena TsoyGlobal Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0001-8786-1791
Ganna BlazhenetsDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-2419-7373
Piyush MaitiDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.ORCID 0009-0002-8006-1032
Jiaxiuxiu ZhangDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-2572-2555
Isabel Elaine AllenGlobal Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, California, USA.
Salma RochaDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Ranjani P ShankarDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Alinda AmuiriDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Mawuli LawsonGlobal Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, California, USA.
Paul AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Laurel BeckettDepartment of Public Health Sciences, University of California, Davis, Davis, California, USA.
Ani EloyanDepartment of Biostatistics, School of Public Health, Brown University, Providence, Rhode Island, USA.
Dustin B HammersDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kala KirbyDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Robert KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Walter A KukullDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Arthur W TogaLaboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
Alireza AtriBanner Sun Health Research Institute, Sun City, Arizona, USA.
David ClarkDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Ranjan DuaraWien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Ian GrantDepartment of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Lawrence S HonigTaub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
Erik C B JohnsonEmory University School of Medicine, Atlanta, Georgia, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Joseph MasdeuNantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
Mario F MendezDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Erik MusiekDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Chiadi U OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meghan RiddleDepartment of Psychiatry, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Emily RogalskiHealthy Aging & Alzheimer's Research Care Center, Department of Neurology, University of Chicago, Chicago, Illinois, USA.
Steven SallowayDepartment of Psychiatry, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Sharon J ShaDepartment of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
Raymond Scott TurnerDepartment of Neurology, Georgetown University, Washington, District of Columbia, USA.
Thomas S WingoDepartment of Neurology, UC Davis Alzheimer's Disease Research Center, University of California, Davis, Davis, California, USA.
David A WolkDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kyle WomackDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Joel H KramerDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Alexandra TouroutoglouDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michael J BrickhouseDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Alexander TauroneCenter for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, Rhode Island, USA.
Maryanne ThangarajahCenter for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, Rhode Island, USA.
Kelly NudelmanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Maria C CarrilloMedical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5958-3445
Liana G ApostolovaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Katherine L PossinGlobal Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, California, USA.
Gil D RabinoviciDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Renaud La JoieGlobal Brain Health Institute (GBHI), University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-2581-8100
LEADS Consortium

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2020 to 2026
$29.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Lisa Goldman Rosas · 2020 to 2026
$29.0M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI · 2020 to 2026
$27.8M
from NIH P30AG062421from NIH P30AG062422from NIH P30AG062677from NIH P30AG066444from NIH P30AG066462from NIH P30AG066507from NIH P30AG066511from NIH P30AG066515from NIH P30AG072976from NIH P30AG072977from NIH P30AG072979from NIH P30AG072980from NIH R21AG080410from NIH R56AG057195from NIH U01AG057195from NIH U24AG021886from NIH U24AG072122from NIH UG3AG090679from the Alzheimer's Association AARG-22-926940from the Alzheimer's Association LDRFP-21-818464from the Alzheimer's Association LDRFP-21-824473from the Alzheimer's Association LEADSGENETICS-19-639372NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS R21 AG080410NIA NIH HHS R35 AG072362NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG057195NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG072122NIA NIH HHS UG3 AG090679NINDS NIH HHS U01 NS128913
6 · The paper itself

Abstract

introductionBrief digital cognitive measures may be a valuable and scalable alternative to traditional tests for improving early detection and disease monitoring in patients with early-onset Alzheimer's disease (EOAD).

methodsWe examined the convergent, diagnostic, and neuroanatomical validity of Tablet-based Cognitive Assessment Tool (TabCAT) tests in the multisite Longitudinal Early-Onset Alzheimer's Disease Study. Four hundred seventy-five participants from 16 sites (83 cognitively unimpaired participants, 146 individuals diagnosed with mild cognitive impairment [MCI], and 246 with mild dementia) underwent TabCAT testing, including two executive/attentional tasks (Match and Flanker) and two visuospatial tasks (Line Length and Line Orientation).

resultsTabCAT tests showed good convergent validity with traditional pen-and-paper tests. Match was the most accurate TabCAT test in differentiating among clinical groups (controls vs. MCI vs. dementia) and predicting amyloid positron emission tomography (PET) positivity in clinically impaired participants. TabCAT tests were associated with regional tau PET patterns. DISCUSSION: TabCAT digital measures have promise for frontline identification of patients with EOAD. HIGHLIGHTS: Four hundred seventy-five participants from 16 US sites underwent tablet-based cognitive assessment. Digital tests assessed executive function and visuospatial abilities. Digital tests correlated with traditional pen-and-paper cognitive tests. Match (test of executive function) differentiated clinical groups. Digital tests were associated with amyloid positron emission tomography (PET) status and regional tau PET patterns.

Indexed as

Alzheimer DiseaseCognitive DysfunctionComputers, HandheldNeuropsychological TestsAgedExecutive FunctionFemaleHumansLongitudinal StudiesMaleMiddle AgedPositron-Emission TomographyReproducibility of Resultsdigital biomarkerearly‐onset Alzheimer's diseaseexecutive functionneuropsychologytau

Identifiers

PMID41395729
PMCPMC12703652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.